Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Radiopharm receives US$2.0 M payment from Lantheus

Monday, August 5, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has announced a receipt of US$2.0 million from Lantheus. This payment is expected to enhance their ongoing clinical studies and development efforts. The collaboration reflects a strong partnership between the two companies, potentially leading to further advancements in their therapeutic programs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm received a significant payment of US$2.0 million from Lantheus.
  • The payment indicates strong collaboration and financial backing.
  • This funding can support ongoing clinical studies and development.

Full Press Release Details

• Announcements
• Periodic Reports
• August 5, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• September 18, 2024
• Announcements
• November 25, 2021
• Announcements
• September 9, 2022
• Announcements
• October 19, 2022

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the amount Radiopharm received from Lantheus?

Radiopharm received a payment of US$2.0 million from Lantheus.

How will the payment from Lantheus benefit Radiopharm?

The payment will support Radiopharm's ongoing clinical studies and development efforts.

What does this payment indicate about Radiopharm's partnership?

The payment reflects a strong collaboration and financial backing between Radiopharm and Lantheus.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Lantheus clinical studies therapeutics
Last updated: Aug 5, 2024